Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Ampio Execs Extend Lockup

By R&D Editors | July 3, 2012

GREENWOOD VILLAGE, Colo. (AP) – Biopharmaceutical company Ampio Pharmaceuticals Inc. said that its CEO and its Chief Scientific Officer have extended an agreement against selling their Ampio shares until January 2013.

The deal between Ampio and its CEO and chairman Michael Macaluso and its CSO and founder David Bar-Or was set to expire on July 15. Bar-Or is also the company’s biggest stockholder.

Macaluso also sought to defuse expectations that a large block of Ampio shares held by former shareholders of DMI Biosciences Inc. will be traded with the recent expiration of a June 30 lockup date.

Bar-Or currently holds about 3.7 million shares, or about 12% of Ampio’s total outstanding stock, according to CapitalIQ. Macaluso holds approximately 2 million shares, or about 6.6 percent of the company’s total outstanding stock.

Macaluso said in a statement that Ampio management is precluded from selling or buying its shares due to the non-public information being created within a company engaging potential collaboration or distribution partners while managing multiple clinical trials and regulatory submissions.

Ampio, which is based in Greenwood Village, Colo., is currently conducting clinical trials on inflammation drug Ampion, eye drug Optina, premature ejaculation treatment Zertane and Zertane-ED. The company is also looking at licensing distribution of the drugs.

Ampio acquired DMI Biosciences in 2010. DMI Biosciences shareholders obtained Ampio stock in that deal.

Macaluso said a large percentage of those shareholders failed to extend their lock-up past Dec. 31, 2011, and were allowed to sell their stock beginning on Jan. 1.

He said shareholders who extended their lock-up until June 30 have been allowed to sell a cumulative 5 percent per month since September 2011. But he said it is inaccurate to expect that a large block of shares will be traded since the passing of the June 30 date.

Date: July 3, 2012
Source: Associated Press

Related Articles Read More >

PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
R&D 100 winner of the day: Portable EnGineered Analytic Sensor with aUtomated Sampling (PEGASUS)
UCLA bioengineers develop new class of human-powered bioelectronics
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars